Cytosorbents (CTSO) Enterprise Value Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) Enterprise Value Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.08 Bn | 175.79 Bn | 6.27 Bn |
| 2 | Stryker | 128.71 Bn | 125.83 Bn | 3.81 Bn |
| 3 | Medtronic | 108.79 Bn | 99.57 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.41 Bn | 66.96 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.34 Bn | 44.67 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn |
| 7 | Dexcom | 28.34 Bn | 27.22 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.87 Bn | 26.29 Bn | - |
| 9 | Koninklijke Philips | 25.43 Bn | 22.31 Bn | 2.07 Bn |
| 10 | Cytosorbents | 22.59 Mn | 17.79 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.39% |
| Dec 31, 2025 | 57.67% |
| Sep 30, 2025 | -15.94% |
| Jun 30, 2025 | -20.63% |
| Mar 31, 2025 | -52.29% |
| Dec 31, 2024 | -4.48% |
| Sep 30, 2024 | 22.24% |
| Jun 30, 2024 | 35.68% |
| Mar 31, 2024 | 54.81% |
| Dec 31, 2023 | 36.19% |
| Sep 30, 2023 | 62.93% |
| Jun 30, 2023 | 56.40% |
| Mar 31, 2023 | 55.72% |
| Dec 31, 2022 | 57.53% |
| Sep 30, 2022 | 63.06% |
| Jun 30, 2022 | 54.02% |
| Mar 31, 2022 | 37.16% |
| Dec 31, 2021 | 27.00% |
| Sep 30, 2021 | 30.62% |
| Jun 30, 2021 | -86.85% |